Inhibition of human cord blood-derived mast cell responses by anti-FcεRI mAb 15/1 versus anti-IgE Omalizumab

Immunology Letters

Volumn 109, Issue 2, 2007, Pages 120-128

  Mirkina, Irina ^a   Schweighoffer, Tamás ^a   Kricek, Franz ^a  

^a Novartis Institutes for BioMedical Research Vienna   (Austria)

Author keywords

Activation marker; Degranulation; IgE receptor; Mast cells; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 15 1; OMALIZUMAB; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; BASOPHIL; CELL ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; CYTOLYSIS; DEGRANULATION; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INHIBITION KINETICS; MAST CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ANAPHYLAXIS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CELL DEGRANULATION; CYTOKINES; FETAL BLOOD; HUMANS; IMMUNOGLOBULIN E; MAST CELLS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RECEPTORS, IGE;

EID: 33947420879     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.02.003     Document Type: Article

References (33)

1. Nechansky A., Robertson M.W., Albrecht B.A., and Apgar J.R. Kricek F: inhibition of antigen-induced mediator release from IgE-sensitized cells by a monoclonal anti-Fc epsilon RI alpha-chain receptor antibody: implications for the involvement of the membrane-proximal alpha-chain region in Fc epsilon RI-mediated cell activation. J Immunol 166 (2001) 5979-5990
2. Galli S.J., Nakae S., and Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 6 (2005) 135-142
3. Gimborn K., Lessmann E., Kuppig S., Krystal G., and Huber M. SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels. J Immunol 174 (2005) 507-516
4. Sayama K., Diehn M., Matsuda K., Lunderius C., Tsai M., Tam S.Y., et al. Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunol 3 (2002) 5
5. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 114 (2004) 527-530
6. Easthope S., and Jarvis B. Omalizumab. Drugs 61 (2001) 253-260
7. Lazaar A.L. Technology evaluation: omalizumab, Genentech/Novartis/Tanox. Curr Opin Mol Ther 5 (2003) 81-89
8. Noga O., Hanf G., and Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131 (2003) 46-52
9. Prieto L., Gutierrez V., Colas C., Tabar A., Perez-Frances C., Bruno L., et al. Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 139 (2006) 122-131
10. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., and Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115 (2005) 459-465
11. Scheinfeld N. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 11 (2005) 2
12. Pichler W.J. Specific and nonspecific (anti-IgE) immunotherapy of allergic diseases. Ther Umsch 58 (2001) 329-336
13. Nechansky A., Aschauer H., and Kricek F. The membrane-proximal part of FcepsilonRIalpha contributes to human IgE and antibody binding-implications for a general structural motif in Fc receptors. FEBS Lett 441 (1998) 225-230
14. Jolly P.S., Bektas M., Olivera A., Gonzalez-Espinosa C., Proia R.L., Rivera J., et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 199 (2004) 959-970
15. Dahl C., Saito H., Nielsen H.V., and Schiotz P.O. The establishment of a combined serum-free and serum-supplemented culture method of obtaining functional cord blood-derived human mast cells. J Immunol Methods 262 (2002) 137-143
16. Austen K.F., and Boyce J.A. Mast cell lineage development and phenotypic regulation. Leuk Res 25 (2001) 511-518
17. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., and Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94 (1999) 2333-2342
18. Shimizu Y., Sakai K., Miura T., Narita T., Tsukagoshi H., Satoh Y., et al. Characterization of 'adult-type' mast cells derived from human bone marrow CD34(+) cells cultured in the presence of stem cell factor and interleukin-6. Interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation. Clin Exp Allergy 32 (2002) 872-880
19. Ali K., Bilancio A., Thomas M., Pearce W., Gilfillan A.M., Tkaczyk C., et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431 (2004) 1007-1011
20. Poole J.A., Matangkasombut P., and Rosenwasser L.J. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 115 (2005) S376-S385
21. Kinet J.P. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17 (1999) 931-972
22. Toru H., Ra C., Nonoyama S., Suzuki K., Yata J., and Nakahata T. Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol 8 (1996) 1367-1373
23. Toru H., Pawankar R., Ra C., Yata J., and Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol 102 (1998) 491-502
24. Toru H., Eguchi M., Matsumoto R., Yanagida M., Yata J., and Nakahata T. Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91 (1998) 187-195
25. Turner H., and Kinet J.P. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 402 (1999) B24-B30
26. Mahmudi-Azer S., Downey G.P., and Moqbel R. Translocation of the tetraspanin CD63 in association with human eosinophil mediator release. Blood 99 (2002) 4039-4047
27. Nishida K., Yamasaki S., Ito Y., Kabu K., Hattori K., Tezuka T., et al. Fc{epsilon}RI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane. J Cell Biol 170 (2005) 115-126
28. Hennersdorf F., Florian S., Jakob A., Baumgartner K., Sonneck K., Nordheim A., et al. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of igE-dependent upregulation. Cell Res 15 (2005) 325-335
29. Nopp A., Johansson S.G., Ankerst J., Bylin G., Cardell L.O., Gronneberg R., et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 61 (2006) 298-302
30. Valent P., Schernthaner G.H., Sperr W.R., Fritsch G., Agis H., Willheim M., et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 179 (2001) 74-81
31. Ching T.T., Hsu A.L., Johnson A.J., and Chen C.S. Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca(2+) entry mechanism. J Biol Chem 276 (2001) 14814-14820
32. Hundley T.R., Gilfillan A.M., Tkaczyk C., Andrade M.V., Metcalfe D.D., and Beaven M.A. Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 104 (2004) 2410-2417
33. Hamilton R.G., Marcotte G.V., and Saini S.S. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 303 (2005) 81-91